Compare

Nanobiotix S.A./€NANO

1D1W1M3M6MYTD1Y5YMAX

About Nanobiotix S.A.

Nanobiotix S.A. is a biotechnology company focusing on developing innovative nanomedicine solutions for cancer therapy. Its core business is centered around the development of NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in cancer treatment. Founded in 2003, Nanobiotix is headquartered in Paris, France. Its strategic positioning lies in its proprietary nanotechnology platform, which aims to address unmet needs in oncology by potentially improving outcomes and safety for patients undergoing radiotherapy. The company operates primarily within the European and U.S. markets, with ongoing clinical trials to expand its therapeutic applications.
Ticker
€NANO
Sector
Health
Primary listing
PAR
Employees
98
Headquarters
Paris, France
Website
www.nanobiotix.com

Nanobiotix S.A. Metrics

BasicAdvanced
€1.4B
-
-€1.09
0.59
-

What the Analysts think about Nanobiotix S.A.

Analyst ratings (Buy, Hold, Sell) for Nanobiotix S.A. stock.
Analyst projections of the future price of Nanobiotix S.A. stock.

Bulls say / Bears say

The FDA accepted a change to J&J’s pivotal NANORAY-312 trial that removes the interim analysis and allows a final analysis with fewer events. Nanobiotix expects that analysis in the same timeframe as the former interim readout, creating a potentially nearer catalyst. (Nanobiotix)
In an early Stage 3 lung cancer cohort, 6 of 7 patients had an overall response and 4 of 7 had a complete response after the full treatment regimen. This is a promising signal for NBTXR3 in combination treatment, although the cohort is very small. (Nanobiotix)
In a 24-patient study of recurrent lung cancer, one-year locoregional control was 79% and one-year overall survival was 70%. No severe adverse events were attributed to NBTXR3 or its injection, supporting further study of the treatment in a difficult re-irradiation setting. (GlobeNewswire)
NANORAY-312 remains an ongoing pivotal trial, not a proven treatment: the trial registry still lists it as recruiting and estimates primary completion in June 2028. Any change to the analysis plan is not evidence that NBTXR3 will meet its efficacy endpoint. (ClinicalTrials.gov)
The 24-patient re-irradiation study recorded two fatal and eight Grade 3 radiation-related adverse events. Although none were attributed to NBTXR3 or its injection, these events underline the safety challenges in this setting. (GlobeNewswire)
Nanobiotix reported a €34.3 million net loss for the first half of 2026 and €14.5 million in interest costs. It says further funding may be needed and could dilute shareholders, so the projected cash runway into 2029 does not remove financing risk. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.

Nanobiotix S.A. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Nanobiotix S.A. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Nanobiotix S.A.

Funds
Fund name
Fund size
€NANO weighting
iShares Ageing Population$AGED
$953M0.10%
iShares Healthcare Innovation£DRDR
$1.3B0.10%
iShares Healthcare Innovation€2B78
$1.2B0.10%
iShares Healthcare Innovation$HEAL
$1.3B0.10%
iShares Ageing Population€AGED
$903M0.10%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.